Annual Total Liabilities
$23.59 M
-$1.53 M-6.10%
December 31, 2021
Summary
- As of February 10, 2025, OPNT annual total liabilities is $23.59 million, with the most recent change of -$1.53 million (-6.10%) on December 31, 2021.
- During the last 3 years, OPNT annual total liabilities has risen by +$11.06 million (+88.30%).
Performance
OPNT Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Quarterly Total Liabilities
$21.45 M
+$2.22 M+11.55%
September 30, 2022
Summary
- As of February 10, 2025, OPNT quarterly total liabilities is $21.45 million, with the most recent change of +$2.22 million (+11.55%) on September 30, 2022.
- Over the past year, OPNT quarterly total liabilities has dropped by -$5.53 million (-20.49%).
Performance
OPNT Quarterly Total Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
High & Low
Earnings dates
Total Liabilities Formula
Total Liabilities = Current Liabilities + Long-Term Liabilities
OPNT Total Liabilities Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -6.1% | -20.5% |
| 3 y3 years | +88.3% | +119.7% |
| 5 y5 years | +203.5% | +217.7% |
OPNT Total Liabilities Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | at high | at low | -9.1% | -10.4% |
| 5 y | 5-year | -6.1% | -75.1% | -20.5% | -79.2% |
| alltime | all time | -6.1% | -100.0% | -20.5% | -100.0% |
Opiant Pharmaceuticals Total Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sep 2022 | - | $21.45 M(+11.5%) |
| Jun 2022 | - | $19.23 M(-8.7%) |
| Mar 2022 | - | $21.06 M(-10.7%) |
| Dec 2021 | $23.59 M(-6.1%) | $23.59 M(-12.6%) |
| Sep 2021 | - | $26.97 M(+6.2%) |
| Jun 2021 | - | $25.40 M(+1.9%) |
| Mar 2021 | - | $24.92 M(-0.8%) |
| Dec 2020 | $25.12 M(+328.4%) | $25.12 M(+274.9%) |
| Sep 2020 | - | $6.70 M(+30.4%) |
| Jun 2020 | - | $5.14 M(+15.3%) |
| Mar 2020 | - | $4.46 M(-24.0%) |
| Dec 2019 | $5.86 M(-53.2%) | $5.86 M(-39.9%) |
| Sep 2019 | - | $9.76 M(+11.4%) |
| Jun 2019 | - | $8.76 M(-7.5%) |
| Mar 2019 | - | $9.47 M(-24.4%) |
| Dec 2018 | $12.53 M(+61.2%) | $12.53 M(+203.5%) |
| Sep 2018 | - | $4.13 M(-35.7%) |
| Jun 2018 | - | $6.42 M(-18.0%) |
| Mar 2018 | - | $7.82 M(+15.8%) |
| Dec 2017 | $7.77 M(+20.1%) | - |
| Oct 2017 | - | $6.75 M(+4.3%) |
| Jul 2017 | $6.47 M(-1.7%) | $6.47 M(+17.4%) |
| Apr 2017 | - | $5.52 M(-21.7%) |
| Jan 2017 | - | $7.05 M(-0.8%) |
| Oct 2016 | - | $7.10 M(+7.8%) |
| Jul 2016 | $6.59 M(-25.8%) | $6.59 M(+6.7%) |
| Apr 2016 | - | $6.17 M(-1.0%) |
| Jan 2016 | - | $6.23 M(-35.8%) |
| Oct 2015 | - | $9.71 M(+9.4%) |
| Jul 2015 | $8.87 M | $8.87 M(+7.4%) |
| Apr 2015 | - | $8.26 M(+16.2%) |
| Jan 2015 | - | $7.11 M(+33.2%) |
| Date | Annual | Quarterly |
|---|---|---|
| Oct 2014 | - | $5.34 M(+58.0%) |
| Jul 2014 | $3.38 M(+106.9%) | $3.38 M(+34.9%) |
| Apr 2014 | - | $2.50 M(+16.5%) |
| Jan 2014 | - | $2.15 M(-2.4%) |
| Oct 2013 | - | $2.20 M(+34.8%) |
| Jul 2013 | $1.63 M(+146.1%) | $1.63 M(+37.3%) |
| Apr 2013 | - | $1.19 M(-1.1%) |
| Jan 2013 | - | $1.20 M(+39.0%) |
| Oct 2012 | - | $865.50 K(+30.4%) |
| Jul 2012 | $663.70 K(+59.5%) | $663.70 K(+24.3%) |
| Apr 2012 | - | $533.80 K(+45.0%) |
| Jan 2012 | - | $368.10 K(+36.5%) |
| Oct 2011 | - | $269.70 K(-35.2%) |
| Jul 2011 | $416.20 K(-36.9%) | $416.20 K(-7.2%) |
| Apr 2011 | - | $448.30 K(-31.3%) |
| Jan 2011 | - | $652.90 K(-27.4%) |
| Oct 2010 | - | $898.90 K(+36.3%) |
| Jul 2010 | $659.40 K(>+9900.0%) | $659.40 K(+38.8%) |
| Apr 2010 | - | $475.00 K(+84.0%) |
| Jan 2010 | - | $258.20 K(+238.4%) |
| Oct 2009 | - | $76.30 K(>+9900.0%) |
| Jul 2009 | $0.00(-100.0%) | $0.00(-100.0%) |
| Apr 2009 | - | $41.20 K(+11.7%) |
| Jan 2009 | - | $36.90 K(+10.1%) |
| Oct 2008 | - | $33.50 K(+18.0%) |
| Jul 2008 | $28.40 K(+170.5%) | $28.40 K(+76.4%) |
| Apr 2008 | - | $16.10 K(+10.3%) |
| Jan 2008 | - | $14.60 K(+32.7%) |
| Oct 2007 | - | $11.00 K(+4.8%) |
| Jul 2007 | $10.50 K | $10.50 K(+400.0%) |
| Apr 2007 | - | $2100.00(>+9900.0%) |
| Jan 2007 | - | $0.00 |
FAQ
- What is Opiant Pharmaceuticals annual total liabilities?
- What is the all time high annual total liabilities for Opiant Pharmaceuticals?
- What is Opiant Pharmaceuticals annual total liabilities year-on-year change?
- What is Opiant Pharmaceuticals quarterly total liabilities?
- What is the all time high quarterly total liabilities for Opiant Pharmaceuticals?
- What is Opiant Pharmaceuticals quarterly total liabilities year-on-year change?
What is Opiant Pharmaceuticals annual total liabilities?
The current annual total liabilities of OPNT is $23.59 M
What is the all time high annual total liabilities for Opiant Pharmaceuticals?
Opiant Pharmaceuticals all-time high annual total liabilities is $25.12 M
What is Opiant Pharmaceuticals annual total liabilities year-on-year change?
Over the past year, OPNT annual total liabilities has changed by -$1.53 M (-6.10%)
What is Opiant Pharmaceuticals quarterly total liabilities?
The current quarterly total liabilities of OPNT is $21.45 M
What is the all time high quarterly total liabilities for Opiant Pharmaceuticals?
Opiant Pharmaceuticals all-time high quarterly total liabilities is $26.97 M
What is Opiant Pharmaceuticals quarterly total liabilities year-on-year change?
Over the past year, OPNT quarterly total liabilities has changed by -$5.53 M (-20.49%)